14 years of historical data (2012–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Soleno Therapeutics, Inc. trades at 100.2x earnings, 16% below its 5-year average of 118.7x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 323%. On a free-cash-flow basis, the stock trades at 0.0x P/FCF, 100% below the 5-year average of 53.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $145692 | $2.5B | $1.8B | $664M | $83M | $164M | $604M | $502M | $179M | $81M | $63M |
| Enterprise Value | $-67270308 | $2.4B | $1.8B | $495M | $69M | $143M | $555M | $481M | $156M | $64M | $60M |
| P/E Ratio → | 100.18 | 118.72 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.00 | 13.21 | — | — | — | — | — | — | — | — | 43.29 |
| P/B Ratio | 4.72 | 5.59 | 7.37 | 4.21 | 8.03 | 9.19 | 13.27 | 33.58 | 5.90 | 3.05 | 18.28 |
| P/FCF | 0.00 | 53.84 | — | — | — | — | — | — | — | — | — |
| P/OCF | 0.00 | 53.75 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.86 | — | — | — | — | — | — | — | — | 41.41 |
| EV / EBITDA | -1.11 | 40.35 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | -1.09 | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 52.39 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Soleno Therapeutics, Inc. earns an operating margin of 32.4%. ROE of 6.0% is modest. ROIC of 15.6% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | 100.1% | -4.0% |
| Operating Margin | 32.4% | 32.4% | — | — | — | — | — | — | — | 0.8% | -938.1% |
| Net Profit Margin | 11.0% | 11.0% | — | — | — | — | — | — | — | 1.0% | -831.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 6.0% | 6.0% | -87.4% | -46.5% | -171.0% | -97.6% | -81.5% | -135.7% | -46.8% | -104.6% | -362.4% |
| ROA | 4.7% | 4.7% | -68.7% | -37.6% | -77.6% | -61.5% | -47.8% | -75.7% | -32.5% | -70.3% | -175.3% |
| ROIC | 15.6% | 15.6% | -142.0% | — | — | — | — | -1898.3% | -128.1% | -180.0% | -1439.3% |
| ROCE | 15.1% | 15.1% | -78.0% | -43.9% | -104.4% | -75.1% | -71.3% | -62.3% | -36.4% | -59.2% | -307.0% |
Solvency and debt-coverage ratios — lower is generally safer
Soleno Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.0x, which is very conservative (99% below the sector average of 3.1x). The company holds a net cash position — cash of $70M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.22 | 0.00 | 0.01 | 0.03 | 0.00 | 0.02 | — | — | — |
| Debt / EBITDA | 0.04 | 0.04 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.15 | -0.14 | -1.07 | -1.40 | -1.17 | -1.08 | -1.37 | -0.76 | -0.64 | -0.79 |
| Net Debt / EBITDA | -1.11 | -1.11 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -1.44 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -812.43 | — | — | — | — | — | -230.66 | — | — |
Net cash position: cash ($70M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
Soleno Therapeutics, Inc.'s current ratio of 5.80x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 14.89x to 5.80x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.80 | 5.80 | 15.68 | 14.89 | 2.14 | 2.80 | 5.83 | 4.26 | 13.14 | 10.38 | 2.23 |
| Quick Ratio | 5.55 | 5.55 | 15.68 | 14.89 | 2.14 | 2.80 | 5.83 | 4.26 | 13.14 | 10.38 | 1.84 |
| Cash Ratio | 4.98 | 4.98 | 15.55 | 14.75 | 2.00 | 2.66 | 5.71 | 4.18 | 12.83 | 9.87 | 1.60 |
| Asset Turnover | — | 0.34 | — | — | — | — | — | — | — | -39.80 | 0.26 |
| Inventory Turnover | 0.05 | 0.05 | — | — | — | — | — | — | — | — | 2.29 |
| Days Sales Outstanding | — | 54.07 | — | — | — | — | — | — | — | — | 33.55 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Soleno Therapeutics, Inc. returns 100.0% to shareholders annually primarily through share buybacks. The earnings yield of 1.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.0% | 0.8% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 1.9% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 12.4% |
| Total Shareholder Yield | 100.0% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 12.4% |
| Shares Outstanding | — | $54M | $40M | $16M | $8M | $5M | $4M | $2M | $1M | $598519 | $206766 |
Compare SLNO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SLNOYou | $145692 | 100.2 | -1.1 | 0.0 | — | 32.4% | 6.0% | 15.6% | 0.0 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SLNO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonSoleno Therapeutics, Inc.'s current P/E ratio is 100.2x. The historical average is 118.7x.
Soleno Therapeutics, Inc.'s current EV/EBITDA is -1.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 40.3x.
Soleno Therapeutics, Inc.'s return on equity (ROE) is 6.0%. The historical average is -147.3%.
Based on historical data, Soleno Therapeutics, Inc. is trading at a P/E of 100.2x. Compare with industry peers and growth rates for a complete picture.
Soleno Therapeutics, Inc. has 32.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Soleno Therapeutics, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.